Drug Combinations of Atovaquone-Proguanil (AP) With ACT

Plasmodium Falciparum Malaria (Drug Resistant) Clinical Trial

— APACT  

Official title:

Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax®) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03726593
• Other study ID #: WR2530
• Status: Recruiting
• Phase: Phase 4
• Start date: October 4, 2018
• Est. completion date: December 30, 2022

Study information

• Verified date: March 2021
• Source: Armed Forces Research Institute of Medical Sciences, Thailand
• Contact: Mariusz Wojnarski, MD
• Phone: +66-84-527-4646
• Email: MARIUSZ.WOJNARSKI.MIL[@]AFRIMS.ORG
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigators are conducting this study due to recent reports of many of existing malaria drugs becoming less effective for treatment of malaria. The drugs may not always kill all the parasites, therefore not all patients with malaria are being cured. The main objective of the study is to find out which malaria drugs and what drug combinations are still effective in Cambodia, an area of multi-drug resistance where 4-5 artemisinin-based combination therapies have shown inadequate response, below that established by the World Health Organization (WHO). New drug combinations (taking more than one drug for malaria at the same time), as long as well tolerated, can provide cure in patients that harbor parasites not responsive to standard first-line medications. Human genetic testing will be done to identify patients who may have suboptimal response to treatments and to study the differences in human gene expression to explain why some persons are at higher risk of complications during treatment. Markers of drug resistance to commonly used antimalarial drugs will also be evaluated and shared with national malaria program (CNM) to better guide future malaria treatment decisions in Cambodia.

Description:

Efficacy to drugs that are currently available and new antimalarial candidates that are in development are threatened by multidrug resistant (MDR) malaria parasites, widely prevalent in Cambodia. Without effective interventions, MDR malaria can pose a substantial public health threat in the years to come. Therefore, accurate, timely and relevant data on antimalarial drug resistance is of critical importance. Prompt, effective and well-tolerated treatment remains one of the cornerstones in the malaria case management. Recent malaria outbreak in Thailand and rise of malaria cases observed in Cambodia in 2017 has brought to the forefront the urgency with which new drug candidates and new combination drug treatments must be identified; otherwise, patients may be left with ineffective treatments. Lack of available alternatives has a potential to result in significant setback to the recent gains in malaria control and malaria elimination efforts. Innovative approaches to treatment proposed here, using current ACTs in combination with non-ACT drugs, such as atovaquone-proguanil, need to be investigated to assess drug tolerability and overall efficacy when used under combination treatment. By early investment in the studies of drugs such as pyronaridine-artesunate (ASPY), in combination with other antimalarials, and drug combinations proposed under this protocol, this study will try to provide the latest evidence on the interventions that are most likely to work, even in areas of MDR, such as Cambodia, and along the Cambodia-Thai border. It is hoped that our approach for using combination treatments will not only provide more effective treatments, but it might prolong the lifespan of the remaining antimalarials and delay the spread of MDR malaria to neighboring countries.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 252
• Est. completion date: December 30, 2022
• Est. primary completion date: August 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Understands Khmer spoken language

• Male or female (18 to 70 years old)

• Microscopic confirmation of asexual stages of Pf or mixed infection with Pf, with baseline asexual parasite densities between 100/µL to 200,000/µL

• Able to take oral medications

• Hemoglobin on day of enrollment =9.0 g/dL

• Agree to follow-up for the anticipated study duration, including a minimum of 3 nights at the medical treatment facility (inpatient hospitalization) and weekly follow-up visits for at least 6 weeks

• If the volunteer is on active duty in the military, the volunteer has written permission from their supervisor or states to have been authorized by his/her supervisor or the local commander to participate; and allow study staff to contact their supervisor to confirm this information

Exclusion Criteria:

• Known allergic reaction to any of the study drugs or history of severe intolerance to any of the antimalarials used in this study.

• Pregnant or lactating females and females of childbearing potential who do not agree to use an acceptable form of contraception during the study period and for 6 weeks following the last dose of the study drug.

• Symptoms of severe vomiting (inability to tolerate oral fluids or oral medications during the previous 8 hours or vomiting >3 times in the last 24 hrs).

• Diagnosis of severe malaria

• Abnormal liver function tests i.e AST or ALT or total bilirubin > 1.5 upper limit of normal (ULN) with nausea AND right upper quadrant abdominal pain OR jaundice on exam

• Isolated AST or ALT or Total Bilirubin >2x ULN

• Known significant cardiovascular, liver or renal abnormality or any other clinically significant illness, which in the opinion of the investigator would place the volunteer at significantly higher risk

• Treatment for malaria within the last 4 weeks

• Unable to provide informed consent

• Judged by the investigator to be otherwise unsuitable for study participation (to include, but not limited to, taking other medications that are known to cause serious drug-drug interactions with the study drugs, as determined by the study physician, or having suspected medical condition or taking other drugs that may affect test results interpretation or put the volunteer at much higher risk)

Related Conditions & MeSH terms

• Malaria
• Malaria, Falciparum
• Plasmodium Falciparum Malaria (Drug Resistant)

Intervention

Drug:
• Artesunate and Pyronaridine
Standard weight based dosing
• Atovaquone Proguanil and Artesunate Pyronaridine
Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
• Atovaquone Proguanil and Artesunate Mefloquine
Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)

Locations

Country	Name	City	State
Cambodia	Anlong Veng Referral Hospital	Ânlóng Vêng
Cambodia	Kratie Referral Hospital	Kratie
Cambodia	Stung Treng Referral Hospital	Stung Treng

Sponsors (3)

Lead Sponsor	Collaborator
Armed Forces Research Institute of Medical Sciences, Thailand	National Center for Parasitology, Entomology, and Malaria Control (CNM), Naval Medical Research Unit-2 (NAMRU-2)

Country where clinical trial is conducted

Cambodia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	42-day polymerase chain reaction (PCR) corrected adequate clinical and parasitological response (ACPR), following treatment with ASPY and new drug combinations (AP+ACTs).		6 weeks
Secondary	Prevalence of molecular markers of drug resistance		Day of enrollment and day of malaria recurrence up to 8 weeks
Secondary	Drug susceptibility testing of parasite isolates against standard antimalarial drugs	Ex vivo drug susceptibility testing	Day of enrollment and day of malaria recurrence up to 8 weeks
Secondary	Pharmakokinetics of each study drug - (Cmax)	Peak plasma concentration (Cmax) for study drugs	multiple time points up to 8 weeks
Secondary	Pharmakokinetics of each study drug - (AUC)	Area under the plasma concentration versus time curve (AUC)	multiple time points up to 8 weeks
Secondary	Pharmakokinetics of each study drug - volume of distribution	volume of distribution for study drugs	multiple time points throughout 6 weeks of follow up
Secondary	Pharmakokinetics of each study drug - (T1/2)	elimination half-life (T1/2) for study drugs	multiple time points up to 8 weeks
Secondary	Kaplan Meier survival analysis of asexual blood stage parasitemia and sexual stage gametocytes		6 weeks
Secondary	Gametocyte carriage rates on days 0, 1, 2, 3, and weeks 1 through 6 for each treatment arm		Days 0, 1, 2, 3, and weekly, up to week 8
Secondary	The incidence of hepatotoxicity events for each treatment arm	Alanine aminotransferase (ALT)>5 times the upper limit of normal (ULN) or percent of volunteers meeting the Hy's law definition (ALT or aspartate aminotransferase [AST] >3 x ULN and total bilirubin >2 x ULN) at any post-dose time point within 6 weeks of follow up	Day 3 and week 6
Secondary	Rates of treatment-related adverse events		6 weeks
Secondary	Severity of treatment-related adverse events	Grade 1 - mild, Grade 2 - moderate, Grade 3 - severe, Grade 4- life threatening	6 weeks
Secondary	Number of participants who say they are willing to take the same drug combination in the future		day 2 and week 6
Secondary	Point efficacy with 95% Confidence Interval against blood stage malaria infection classified according to the WHO malaria treatment outcome classifications (ETF, LTF, LCTF, LPTF)		4 weeks, 6 weeks, and 8 weeks
Secondary	Incidence of Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency	Comparative incidence of G6PD deficiency in the study population as determined by G6PD rapid-diagnostic tests (RDTs) and quantitative tests, to include sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) for each of the point-of-care tests against 10%, 30%, and 60% thresholds of normal G6PD activity	Enrollment
Secondary	Number of infected mosquitos following membrane feeding		Day 0, Day 3, Day 7, and on day of malaria recurrence up to 8 weeks